GB202003618D0 - Gene Therapy - Google Patents

Gene Therapy

Info

Publication number
GB202003618D0
GB202003618D0 GBGB2003618.2A GB202003618A GB202003618D0 GB 202003618 D0 GB202003618 D0 GB 202003618D0 GB 202003618 A GB202003618 A GB 202003618A GB 202003618 D0 GB202003618 D0 GB 202003618D0
Authority
GB
United Kingdom
Prior art keywords
gene therapy
therapy
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2003618.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bristol
Syncona Investment Management Ltd
Original Assignee
University of Bristol
Syncona Investment Management Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bristol, Syncona Investment Management Ltd filed Critical University of Bristol
Priority to GBGB2003618.2A priority Critical patent/GB202003618D0/en
Publication of GB202003618D0 publication Critical patent/GB202003618D0/en
Priority to JP2022554473A priority patent/JP2023517934A/ja
Priority to IL296255A priority patent/IL296255A/en
Priority to CA3171232A priority patent/CA3171232A1/en
Priority to US17/909,839 priority patent/US12589167B2/en
Priority to EP21711944.5A priority patent/EP4118216A1/en
Priority to PCT/GB2021/050633 priority patent/WO2021181118A1/en
Priority to AU2021234169A priority patent/AU2021234169A1/en
Priority to BR112022018036A priority patent/BR112022018036A2/pt
Priority to MX2022011295A priority patent/MX2022011295A/es
Priority to CN202180020240.6A priority patent/CN115427578B/zh
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
GBGB2003618.2A 2020-03-12 2020-03-12 Gene Therapy Ceased GB202003618D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GBGB2003618.2A GB202003618D0 (en) 2020-03-12 2020-03-12 Gene Therapy
CN202180020240.6A CN115427578B (zh) 2020-03-12 2021-03-12 基因疗法
US17/909,839 US12589167B2 (en) 2020-03-12 2021-03-12 AAV gene therapy vector with podocyte-specific promoter
IL296255A IL296255A (en) 2020-03-12 2021-03-12 Gene therapy
CA3171232A CA3171232A1 (en) 2020-03-12 2021-03-12 Gene therapy
JP2022554473A JP2023517934A (ja) 2020-03-12 2021-03-12 遺伝子治療
EP21711944.5A EP4118216A1 (en) 2020-03-12 2021-03-12 Gene therapy
PCT/GB2021/050633 WO2021181118A1 (en) 2020-03-12 2021-03-12 Gene therapy
AU2021234169A AU2021234169A1 (en) 2020-03-12 2021-03-12 Gene therapy
BR112022018036A BR112022018036A2 (pt) 2020-03-12 2021-03-12 Vetor viral, e, terapia gênica de vetor viral
MX2022011295A MX2022011295A (es) 2020-03-12 2021-03-12 Terapia genica.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2003618.2A GB202003618D0 (en) 2020-03-12 2020-03-12 Gene Therapy

Publications (1)

Publication Number Publication Date
GB202003618D0 true GB202003618D0 (en) 2020-04-29

Family

ID=70453740

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2003618.2A Ceased GB202003618D0 (en) 2020-03-12 2020-03-12 Gene Therapy

Country Status (11)

Country Link
US (1) US12589167B2 (https=)
EP (1) EP4118216A1 (https=)
JP (1) JP2023517934A (https=)
CN (1) CN115427578B (https=)
AU (1) AU2021234169A1 (https=)
BR (1) BR112022018036A2 (https=)
CA (1) CA3171232A1 (https=)
GB (1) GB202003618D0 (https=)
IL (1) IL296255A (https=)
MX (1) MX2022011295A (https=)
WO (1) WO2021181118A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202003618D0 (en) 2020-03-12 2020-04-29 Univ Bristol Gene Therapy
EP4273243A1 (en) 2022-05-02 2023-11-08 Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca Nucleic acid constructs and vectors for podocyte specific expression
GB202304841D0 (en) * 2023-03-31 2023-05-17 Purespring Therapeutics Ltd Promoter
CN116590345B (zh) * 2023-05-06 2024-01-30 北京中医药大学 永生化小鼠足细胞系及其制备方法、分化方法和应用
GB202309913D0 (en) * 2023-06-29 2023-08-16 Purespring Therapeutics Ltd Polynucleotides, avv vectors, and pharmaceutical compositions for treating nephrotic syndrome
GB202309908D0 (en) * 2023-06-29 2023-08-16 Purespring Therapeutics Ltd Polynucleotides, aav vectors, and pharmaceutical compositions for treating complement-mediated kidney diseases
GB202309914D0 (en) * 2023-06-29 2023-08-16 Purespring Therapeutics Ltd Promoters
GB202309909D0 (en) * 2023-06-29 2023-08-16 Purespring Therapeutics Ltd Regulatory elements
WO2025168940A1 (en) * 2024-02-07 2025-08-14 Purespring Therapeutics Limited Vectors
WO2025193938A1 (en) * 2024-03-13 2025-09-18 Oregon Health & Science University Delivery of type iv collagen alpha chain using a split intein dual aav vector

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL332875A1 (en) 1996-10-17 1999-10-25 Oxford Biomedica Ltd Retroviral vectors
US20060281090A1 (en) 2003-05-01 2006-12-14 University Of Washington Uw Tech Transfer- Invention Licensing Capsid-modified adenovirus vectors and methods of using the same
WO2005012351A2 (en) 2003-08-01 2005-02-10 The Brigham And Women's Hospital, Inc. Novel functions for decay accelerating factor (daf) in inflammation
EP2357254A1 (en) 2005-02-14 2011-08-17 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
WO2007056435A2 (en) 2005-11-08 2007-05-18 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
WO2008136547A1 (en) 2007-05-07 2008-11-13 University Of Ulsan Foundation For Industry Cooperation Method of preventing or treating body weight disorders by employing clusterin
ES2457822T3 (es) 2007-11-08 2014-04-29 The General Hospital Corporation Procedimientos y composiciones de tratamiento de enfermedades proteinúricas
EP2601288B1 (en) 2010-08-05 2016-04-06 Wisconsin Alumni Research Foundation Simplified basic media for human pluripotent cell culture
US8852936B2 (en) 2012-09-21 2014-10-07 Laurantis Pharma Oy Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery
TW201506036A (zh) 2013-08-14 2015-02-16 Laurantis Pharma Oy Vegf-c及ccbe1之治療用途
CA2955481A1 (en) 2014-07-25 2016-01-28 Goldfinch Biopharma, Inc. Collagen iv replacement
EP3526333A4 (en) * 2016-10-13 2020-07-29 University of Massachusetts AAV CAPSIDE DESIGNS
CN107011424B (zh) 2017-03-14 2020-07-03 华南师范大学 斜带石斑鱼补体c1inh基因、载体、重组菌株和蛋白及其应用
GB201706808D0 (en) 2017-04-28 2017-06-14 Univ Newcastle Modified complement proteins and uses thereof
EP3635121A1 (en) * 2017-06-02 2020-04-15 Institut National de la Sante et de la Recherche Medicale (INSERM) Viral vector combining gene therapy and genome editing approaches for gene therapy of genetic disorders
CN111788311A (zh) 2017-10-20 2020-10-16 双子治疗公司 用于治疗年龄相关性黄斑变性的组合物和方法
RU2675861C1 (ru) 2017-11-22 2018-12-25 Лев Иосифович Шагам Способ прогнозирования наличия мутации гена col4a5 у пациентов с предполагаемым диагнозом "синдром альпорта"
EP3856763A1 (en) * 2018-09-28 2021-08-04 Massachusetts Institute of Technology Collagen-localized immunomodulatory molecules and methods thereof
EP3861010A1 (en) * 2018-10-02 2021-08-11 Voyager Therapeutics, Inc. Redirection of tropism of aav capsids
CA3117551A1 (en) 2018-10-23 2020-04-30 Gemini Therapeutics Inc. Compositions and methods for treating age-related macular degeneration and other diseases
RU2714763C1 (ru) 2018-11-08 2020-02-19 Генетик Диагностикс Энд Терапи 21 Лтд Генотерапевтический ДНК-вектор для таргетной генной терапии, способ его получения (варианты), штамм для его производства, способ его получения
GB201900702D0 (en) 2019-01-18 2019-03-06 Univ Bristol Therapy
GB202003618D0 (en) 2020-03-12 2020-04-29 Univ Bristol Gene Therapy
GB202010009D0 (en) 2020-06-30 2020-08-12 Syncona Investment Man Ltd Vector
GB202103470D0 (en) 2021-03-12 2021-04-28 Univ Bristol Promoter

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Mini-Dystrophin Gene in the Canine Model", HUM GENE THER., vol. 29, no. 3, March 2018 (2018-03-01), pages 299 - 311
LIN XSUH JHGO GMINER JH: "Feasibility of Repairing Glomerular Basement Membrane Defects in Alport Syndrome", JASN, vol. 25, no. 4, April 2014 (2014-04-01), pages 687 - 692
LUO, X.HALL, G.LI, S.BIRD, A.LAVIN, P. J.WINN, M. P.KEMPER, A. R.BROWN, T. T.KOEBERL, D. D.: "Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector", MOL THER, vol. 19, 2011, pages 1961 - 70
MCCLEMENTS MEMACLAREN RE: "Adeno-associated Virus (AAV) Dual Vector Strategies for Gene Therapy Encoding Large Transgenes", YALE J BIOL MED., vol. 90, no. 4, 19 December 2017 (2017-12-19), pages 611 - 623, XP055574379
MOELLER, M. J.SANDEN, S. K.SOOFI, A.WIGGINS, R. C.HOLZMAN, L. B.: "Two gene fragments that direct podocyte-specific expression in transgenic mice", J AM SOC NEPHROL, vol. 13, 2002, pages 1561 - 7
PICCONI, J. L.MUFF-LUETT, M. A.WU, D.BUNCHMAN, E.SCHAEFER, F.BROPHY, P. D.: "Kidney-specific expression of GFP by in-utero delivery of pseudotyped adeno-associated virus 9", MOLECULAR THERAPY. METHODS & CLINICAL DEVELOPMENT, vol. 1, 2014, pages 14014
ROCCA, C. J.UR, S. N.HARRISON, F.CHERQUI, S.: "rAAV9 combined with renal vein injection is optimal for kidney-targeted gene delivery: conclusion of a comparative study", GENE THERAPY, vol. 21, 2014, pages 618 - 628, XP055676072, DOI: 10.1038/gt.2014.35
SCHAMBACH, A.BOHNE, J.BAUM, C.HERMANN, F. G.EGERER, L.VON LAER, D.GIROGLOU, T.: "Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression", GENE THERAPY, vol. 13, 2005, pages 641
SCHIEVENBUSCH, S.STRACK, I.SCHEFFLER, M.NISCHT, R.COUTELLE, O.HOSEL, M.HALLEK, M.FRIES, J. W. U.DIENES, H.-P.ODENTHAL, M.: "Combined Paracrine and Endocrine AAV9 mediated Expression of Hepatocyte Growth Factor for the Treatment of Renal Fibrosis", MOLECULAR THERAPY, vol. 18, 2010, pages 1302 - 1309

Also Published As

Publication number Publication date
EP4118216A1 (en) 2023-01-18
CA3171232A1 (en) 2021-09-16
US12589167B2 (en) 2026-03-31
CN115427578A (zh) 2022-12-02
WO2021181118A1 (en) 2021-09-16
AU2021234169A1 (en) 2022-10-06
US20240197917A1 (en) 2024-06-20
JP2023517934A (ja) 2023-04-27
IL296255A (en) 2022-11-01
MX2022011295A (es) 2022-11-14
BR112022018036A2 (pt) 2022-11-01
CN115427578B (zh) 2026-03-17

Similar Documents

Publication Publication Date Title
GB202003618D0 (en) Gene Therapy
GB202114972D0 (en) Gene therapy
GB201905301D0 (en) Gene therapy
IL279685A (en) Gene therapy
GB202113079D0 (en) New therapy
GB201802326D0 (en) Gene therapy
GB202103164D0 (en) Therapy
GB202002639D0 (en) Therapy
GB202206346D0 (en) Gene therapy
GB202010894D0 (en) Gene therapy
GB202003109D0 (en) Gene therapy
GB202002202D0 (en) Gene therapy
GB201817470D0 (en) Gene therapy
GB202111035D0 (en) Therapy
GB202108303D0 (en) Therapy
IL310018A (en) KCNV2 gene therapy
GB202114973D0 (en) Gene therapy
GB202003536D0 (en) Gene therapy
GB202003120D0 (en) Gene therapy
GB202001930D0 (en) Gene therapy
GB202316264D0 (en) Gene therapy
GB202315668D0 (en) Gene therapy
GB202214445D0 (en) Gene therapy
GB202212092D0 (en) Gene therapy
HK40108664A (en) Kcnv2 gene therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)